

#1

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC10790A		SERIAL NO. 09/938,391			
								APPLICANT TONG, ET AL.					
								FILING DATE AUGUST 24, 2001		GROUP 1636			
U.S. PATENT DOCUMENTS													
EXAMINER INITIALS	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SL	4	1	0	9	4	9	6	8/78	Alleman, et al.				
SL	4	2	1	5	0	5	1	7/80	Schroeder, et al.				
SL	4	3	7	6	1	1	0	3/83	David, et al.				
SL	4	6	5	6	1	2	7	4/87	Mundy				
SL	4	6	8	3	1	9	5	7/87	Mullis, et al.				
SL	4	6	8	3	2	0	2	7/87	Mullis				
SL	4	8	1	6	3	9	7	3/89	Boss, et al.				
SL	4	8	1	6	5	6	7	3/89	Cabilly, et al.				
SL	4	8	5	1	3	3	1	7/89	Vary, et al.				
SL	4	8	7	3	1	9	1	10/89	Wagner, et al.				
SL	4	9	4	6	7	7	8	8/90	Ladner, et al.				
SL	5	0	7	5	2	1	7	12/91	Weber				
SL	5	0	9	3	2	4	6	3/92	Cech, et al.				
SL	5	2	2	5	5	3	9	7/93	Winter				
SL	5	2	7	2	0	5	7	12/93	Smulson, et al.				
SL	5	2	7	2	0	7	1	12/93	Chappel				
SL	5	3	6	4	7	5	9	11/94	Caskey, et al.				
SL	5	3	9	9	3	4	9	3/95	Paunescu, et al.				
SL	5	4	5	9	0	3	9	10/95	Modrich, et al.				
SL	5	4	9	8	5	3	1	3/96	Jarrell				
SL	5	5	4	5	8	0	6	8/96	Lonberg, et al.				
SL	5	5	6	9	8	2	5	10/96	Lonberg, et al.				
SL	5	5	8	5	0	8	9	12/96	Queen, et al.				
SL	5	6	2	5	1	2	6	4/97	Lonberg, et al.				
SL	5	6	3	3	4	2	5	5/97	Lonberg, et al.				
SL	5	6	6	1	0	1	6	8/97	Lonberg, et al.				
SL													

EXPRESS MAIL NO. EL162815958US


INFORMATION DISCLOSURE CITATION LIST.DOT, 3/99

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC10790A					SERIAL NO. 09/938,391				
APPLICANT TONG, ET AL.										FILING DATE AUGUST 24, 2001					GROUP 1636				

OFFICE
 MAY 06 2002
 PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
2		0	1	2	5	0	2	3	6/91	EP				
2		0	1	7	1	4	9	6	5/93	EP				
2		0	1	7	3	4	9	4	8/85	EP				
2		0	1	8	4	1	8	7	6/86	EP				
2		8	6	0	1	5	3	3	3/86	PCT				
2		8	7	0	2	6	7	1	5/87	PCT				
2		8	8	0	4	3	0	0	6/88	PCT				
2		8	8	0	9	8	1	0	12/88	PCT				
2		8	9	1	0	1	3	4	11/89	PCT				
2		9	0	1	1	3	6	4	10/90	PCT				
2		9	1	0	2	0	8	7	2/91	PCT				
2		9	1	0	6	6	6	7	5/91	PCT				
2		9	2	1	5	7	1	2	9/92	PCT				
2		9	4	1	6	1	0	1	7/94	PCT				
2		9	5	0	0	6	6	9	1/95	PCT				
2		9	5	1	1	9	9	5	5/95	PCT				
2		0	0	1	1	0	3	3	3/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
1.	2	Auerbach, et al.; Angiogenesis Inhibition: A Review; Pharmac. Ther.; Vol. 63, p. 265-311 (1994).
2.	2	Ribatti, et al.; Angiogenesis under normal and pathological conditions; Haematologica; 76:311-320 (1991).
3.	2	Risau; Mechanisms of Angiogenesis; Nature 386:671-674 (1997).
4.	2	Folkman; Angiogenesis in cancer, vascular, rheumatoid and other disease; Nature Medicine; 1(1): 27-31 (1995).
5.	2	Isner; Cancer and Atherosclerosis; Circulation; 99(13): 1653-1655 (1999).
6.	2	Koch; Arthritis & Rheumatism; Arthritis & Rheumatism; 41(6):951-962 (1998).
7.	2	Walsh; Angiogenesis and arthritis; Rheumatology; 38(2):103-112 (1999).
8.	2	Ware, et al.; Angiogenesis in ischemic heart disease; Nature Medicine; 3(2):158-164 (1997).



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP

9.	Q	Folkman; How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Research; 46(2):467-473 (1986).
10.	Q	Folkman; What is the evidence that tumors are angiogenesis dependent; J. of the Nat. Cancer Inst.; 83(1):4-6 (1990).
11.	Q	Folkman; The role of angiogenesis in tumor growth; Seminars in Cancer Biology; 3(2):65-71 (1992).
12.	Q	Zetter; Angiogenesis and tumor metastasis; Annu. Rev. Med.; 49:407-424 (1998).
13.	Q	Folkman; Angiogenesis in cancer, vascular, rheumatoid and other disease; Nat. Med; 1(1):27-31 (1995).
14.	Q	M. S. O'Reilly, et al.; Endostatin: An endogenous inhibitor of angiogenesis and tumor growth; Cell; 88(2):277-285 (1997).
15.	Q	M. S. O'Reilly, et al.; Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma; Cell; 79(2):315-328 (1994).
16.	Q	Boehm, et al.; Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance; Nature; 390(6658):404-407 (1997).
17.	Q	Fidler, et al.; The implications of angiogenesis for the biology and therapy of cancer metastasis; Cell; 79(2):185-188 (1994).
18.	Q	Gastl, et al.; Angiogenesis as a target for tumor treatment; Oncology; 54(3):177-184 (1997).
19.	Q	Van Hinsbergh, et al.; Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors; Ann. Oncol.; 10 Suppl. 4:60-63 (1999).
20.	Q	Klement, et al.; Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity; The J. of Clinical Invest.; 105(8):R15-24 (2000).
21.	Q	Browder, et al.; Antiangiogenic Scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer; Cancer Research; 60:1878-1886; (2000).
22.	Q	Arap, et al.; Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model; Science; 279(5349):377-380 (1998).
23.	Q	Mauceri, et al.; Combined effects of angiostatin and ionizing radiation in antitumour therapy; Nature; 394(6690):287-291 (1998).
24.	Q	Bronson; Variation in age at death of dogs of different sexes and breeds; Am. J. Vet. Res.; 43(11):2057-2059 (1982).
25.	Q	Bostock; Canine and feline mammary neoplasms; Br. Vet. J.; 142(6):506-515 (1986).
26.	Q	Bostock; Neoplasms of the skin and subcutaneous tissues in dogs and cats; Br. Vet. J.; 142(1):1-19 (1986).
27.	Q	MacEwen; Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment; Cancer and Metastasis Reviews; 9(2):125-136 (1990).
28.	Q	Karlin, et al.; Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes; Proc. Natl. Acad. Sci.; 87:2264-2268 (1990).
29.	Q	Karlin, et al.; Applications and statistics for multiple high-scoring segments in molecular sequences; Proc. Natl. Acad. Sci.; 90:5873-5877 (1993).
30.	Q	Altschul, et al.; Basic Local Alignment Search Tool; J. Mol. Biol.; 215:403-410 (1990).
31.	Q	Altschul, et al.; Gapped BLAST and PSI-BLAST: a new generation of protein database search programs; Nucleic Acids Research; 25(17):3389-3402 (1997).
32.	Q	Myer, et al.; Optimal alignments in linear space; CABIOS; 4:11-17 (1988).



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP
33.	Sc		Ruther, et al.; Easy identification of cDNA clones; EMBO Journal; 2(10):1791-1794 (1983).	
34.	Sc		Inouye, et al.; Up-promoter mutations in the lpp gene of escherichia coli; Nucleic Acids Research; 13(9):3101-3109 (1985).	
35.	Sc		G. Van Heeke, et al.; Expression of human asparagine synthetase in escherichia coli; The J. of Biological Chemistry; 264:5503-5509 (1989).	
36.	Sc		Smith, et al.; Molecular engineering of the autographa californica nuclear polyhedrosis virus genome: Deletion mutations within the polyhedrin gene; J. of Virology; 46:584-593 (1983).	
37.	Sc		Logan, et al.; Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection; 81:3655-3659 (1984).	
38.	Sc		Bitter, et al.; Expression and secretion vectors for yeast; Methods in Enzymology; 153:516-544 (1987).	
39.	Sc		Wigler, et al.; Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells; Cell; 11:223-232 (1977).	
40.	Sc		Szybalska, et al.; Genetics of human cell lines, IV; Proc. Natl. Acad. Sci.; 48:2026-2034 (1962).	
41.	Sc		Lowy, et al.; Isolation of transforming DNA: cloning the hamster aprt gene; Cell; 22:817-823 (1980).	
42.	Sc		Wigler, et al.; Transformation of mammalian cells with an amplifiable dominant-acting gene; Proc. Natl. Acad. Sci.; 77(6):3567-3570 (1980).	
43.	Sc		O'Hare, et al.; Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase; Proc. Natl. Acad. Sci.; 78:1527-1531 (1981).	
44.	Sc		Mulligan, et al.; Selection for animal cells that express the escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase; Proc. Natl. Acad. Sci.; 78(4):2072-2076 (1981).	
45.	Sc		Colbere-Garapin, et al.; A new dominant hybrid selective marker for higher eukaryotic cells; J. Mol. Biol.; 150:1-13 (1981).	
46.	Sc		Santerre, et al.; Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells; Gene; 30:147-156 (1984).	
47.	Sc		Janknecht, et al.; Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus; Proc. Natl. Acad. Sci.; 88:8972-8976 (1991).	
48.	Sc		H. Van Der Putten, et al.; efficient insertion of genes into the mouse germ line via retroviral vectors; Proc. Natl. Acad. Sci.; 82:6148-6152 (1985).	
49.	Sc		Thompson, et al.; Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells; Cell; 56:313-321 (1989).	
50.	Sc		C. W. Lo; Transformation by iontophoretic microinjection of DNA: Multiple integrations without tandem insertions; Molecular and Cellular Biology; 3(10):1803-1814 (1983).	
51.	Sc		Lavitrano, et al.; Sperm cells as vectors for introducing foreign DNA into eggs: Genetic transformation of mice; Cell; 57:717-723 (1989).	
52.	Sc		Gordon; Transgenic animals; Intl. Rev. Cytol.; 115:171-229 (1989).	
53.	Sc		Campbell, et al.; Sheep cloned by nuclear transfer from a cultured cell line; Nature; 380(7):64-66 (1996).	
54.	Sc		I. Wilmut, et al.; Viable offspring derived from fetal and adult mammalian cells; Nature; 385:810-813 (1997).	
55.	Sc		Lakso, et al.; Targeted oncogene activation by site-specific recombination in transgenic mice; Proc. Natl. Acad. Sci.; 89:a6232-6236 (1992).	




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP 1626
56.	☒		Gu, et al.; Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting; Science; 265:103-106 (1994).	
57.	☒		Kohler, et al.; Continuous cultures of fused cells secreting antibody of predefined specificity; Nature; 256:495-497 (1975).	
58.	☒		Kozbor, et al.; The production of monoclonal antibodies from human lymphocytes; Immunology Today; 4(3):72-79 (1983).	
59.	☒		Cote, et al.; Generation of human monoclonal antibodies reactive with cellular antigens; Proc. Natl. Acad. Sci.; 80:2026-2030 (1983).	
60.	☒		Cole, et al.; The EBV-Hybridoma technique and its application to human lung cancer; Monoclonal Antibodies and Cancer Therapy; Pages 77-96 (1985).	
61.	☒		Better, et al.; Escherichia coli secretion of an active chimeric antibody fragment; Science; 240:1041-1043 (1988).	
62.	☒		Liu, et al.; Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells; Proc. Natl. Acad. Sci.; 84:3439-3443 (1987).	
63.	☒		Liu, et al.; Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity; The J. of Immunol.; 139:3521-3526 (1987).	
64.	☒		Sun, et al.; Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A; Proc. Natl. Acad. Sci.; 84:214-218 (1987).	
65.	☒		Nishimura, et al.; Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen; Cancer Research; 47:999-1005 (1987).	
66.	☒		Wood, et al.; The synthesis and in vivo assembly of functional antibodies in yeast; Nature; 314(4):446-449 (1985).	
67.	☒		Shaw, et al.; Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses; J. Natl. Cancer Inst.; 80:1553-1559 (1988).	
68.	☒		S. L. Morrison; Transfectomas provide novel chimeric antibodies; Science; 229:1202-1207 (1985).	
69.	☒		Oi, et al.; Chimeric antibodies; Bio/Techniques; 4:214-221 (1986).	
70.	☒		Jones, et al.; Replacing the complementarity-determining regions in a human antibody with those from a mouse; Nature; 321:552-525 (1986).	
71.	☒		Verhoeven, et al.; Reshaping human antibodies: Grafting an antilysozyme activity; Science; 239:1534-1536 (1988).	
72.	☒		Beidler, et al.; Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen; The J. of Immunology; 141:4053-4060 (1988).	
73.	☒		Lonberg, et al.; Human antibodies from transgenic mice; Int. Rev. Immunol; 13:65-93 (1995).	
74.	☒		Jespersen, et al.; Guiding the Selection of human antibodies from phage display repertoires to a single epitope of an antigen; Bio/technology; 12:899-903 (1994).	
75.	☒		Bird, et al.; Single-chain antigen-binding proteins; Science; 242:423-426 (1988).	
76.	☒		Huston, et al.; Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in escherichia coli; Proc. Natl. Acad. Sci.; 85:5879-5883 (1988).	
77.	☒		Ward, et al.; Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli; Nature; 334:544-546 (1989).	
78.	☒		Huse, et al.; Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda; Science; 246:1275-1281 (1989).	



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP 1636

79.	SL	Cronin, et al.; Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays; Human Mutation; 7:244-255 (1996).
80.	SL	Orita, et al.; Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms; Proc. Natl. Acad. Sci.; 86:2766-2770 (1989).
81.	SL	M. Grompe; The rapid detection of unknown mutations in nucleic acids; Nature Genetics; 5:111-117 (1993).
82.	SL	Landegren, et al.; A ligase-mediated gene detection technique; Science; 241:1077-1080 (1988).
83.	SL	Nickerson, et al.; Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay; Proc. Natl. Acad. Sci.; 87:8923-8927 (1990).
84.	SL	Pastinen, et al.; Minisequencing: A specific tool for DNA analysis and diagnostics on oligonucleotide arrays; Genome Research; 7:606-614 (1997).
85.	SL	Pastinen, et al.; Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation; Clinical Chemistry; 42(9):1391-1397 (1996).
86.	SL	Jalanko, et al.; Screening for defined cystic fibrosis mutations by solid-phase minisequencing; Clin. Chem.; 38(1):39-42 (1992).
87.	SL	Shumaker, et al.; Mutation detection by solid phase primer extension; Human Mutation; 7:346-354 (1996).
88.	SL	P. D'Eustachio, et al.; Somatic cell genetics and gene families; Science; 220:919-924 (1983).
89.	SL	Fan, et al.; Mapping small DNA sequences by fluorescence in situ hybridization directly on banded metaphase chromosomes; Proc. Natl. Acad. Sci.; 87:6223-6227 (1990).
90.	SL	Popp, et al.; A strategy for the characterization of minute chromosome rearrangements using multiple color fluorescence in situ hybridization with chromosome-specific DNA libraries and YAC clones; Hum. Genetics; 92:527-532 (1993).
91.	SL	Egeland, et al.; Bipolar affective disorders linked to DNA markers on chromosome 11; Nature; 325:783-787 (1987).
92.	SL	A. Voller, et al.; Enzyme immunoassays with special reference to ELISA techniques; J. of Clinical Pathology; 31:507-520 (1978).
93.	SL	J. E. Butler; The amplified ELISA: Principles of and applications for the comparative quantitation of class and subclass antibodies and the distribution of antibodies and antigens in biochemical separates; Method in Enzymology; 73:482-523 (1981).
94.	SL	Platt, et al.; Independent regulation of adipose tissue-specificity and obesity response of the adipin promoter in transgenic mice; The J. of Biological Chemistry; 269(46):28558-28562 (1994).
95.	SL	Lam, et al.; A new type of synthetic peptide library for identifying ligand-binding activity; Nature; 354:82-84 (1991).
96.	SL	Houghten, et al.; Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery; Nature; 354:84-86 (1991).
97.	SL	Songyang, et al.; SH2 Domains recognize specific phosphopeptide sequences; Cell; 72:767-778 (1993).
98.	SL	Landegren et al.; A Ligase-mediated gene detection technique; Science; 241:1077-1079 (1988).
99.	SL	Kowoh, et al.; Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format; Proc. Natl. Acad. Sci.; 86:1173-1177 (1989).
100.	SL	Chien, et al.; The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest; Proc. Natl. Acad. Sci.; 88:9578-9582 (1991).
101.	SL	Nakazawa, et al.; UV and skin cancer: Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement; Proc. Natl. Acad. Sci.; 91:360-364 (1994).




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP 1036

102.	2	Abravaya, et al.; Detection of point mutations with a modified ligase chain reaction (Cap-LCR); Nucleic Acids Research; 23(4):675-682 (1995).
103.	2	Guatelli, et al.; Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication; Proc. Natl. Acad. Sci.; 87:1874-1878 (1990).
104.	2	Lizardi, et al.; Exponential amplification of recombinant-RNA hybridization probes; Bio/Technology; 6:1197-1202 (1988).
105.	2	Cronin, et al.; Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays; Human Mutation; 7L244-255 (1996).
106.	2	Kozal, et al.; Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays; Nature Medicine; 2(7):753-759 (1996).
107.	2	Maxam, et al.; A new method for sequencing DNA; Proc. Natl. Acad. Sci.; 74(2):560-564 (1977).
108.	2	Sanger, et al.; DNA sequencing with chain-terminating inhibitors; Proc. Natl. Acad. Sci.; 74(12):5463-5467 (1977).
109.	2	Naeve, et al.; Accuracy of automated DNA Sequencing: A multi-laboratory comparison of sequencing results; Bio/Techniques; 19(3):448-453 (1995).
110.	2	Griffin, et al.; DNA sequencing; Applied Biochemistry and Biotechnology; 38:147-159 (1993).
111.	2	Myers, et al.; Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA: DNA duplexes; Science; 230:1242-1246 (1985).
112.	2	Cotton, et al.; Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations; Proc. Natl. Acad. Sci.; 85:4397-4401 (1988).
113.	2	Saleeba, et al.; Chemical cleavage of mismatch to detect mutations; Methods in Enzymology; 217:286-295 (1992).
114.	2	Hsu, et al.; Detection of DNA point mutations with DNA mismatch repair enzymes; Carcinogenesis; 15:1657-1662 (1994).
115.	2	Orita, et al.; Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms; Proc. Natl. Acad. Sci.; 86:2766-2770 (1989).
116.	2	R.G.H. Cotton; Current methods of mutation detection; Mutation Research; 285:125-144 (1993).
117.	2	K. Hayashi; PCR-SSCP: A method for detection of mutations; Gata; 9(3):73-79 (1992).
118.	2	Keen, et al.; Rapid detection of single base mismatches as heteroduplexes on hydrolink gels; Trends Genet; 7:5.
119.	2	Myers, et al.; Detection of single base substitutions in total genomic DNA; Nature; 313:495-498 (1985).
120.	2	Saiki, et al.; Analysis of enzymatically amplified β -globin and HLA-DQ α DNA with allele-specific oligonucleotide probes; Nature; 324:163-166 (1986).
121.	2	Saiki, et al.; Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes; Proc. Natl. Acad. Sci.; 86:6230-6234 (1989).
122.	2	Gibbs, et al.; Detection of single DNA base differences by competitive oligonucleotide priming; Nucleic Acid Research; 17(7):2437-2448 (1989).
123.	2	J. Prosser; Detecting single-base mutations; Tibtech; 11:238-246 (1993).
124.	2	Gasparini, et al.; Restriction site generating-polymerase chain reaction (RG-PCR) for the probeless detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations; Molecular and Cellular Probes; 6:1:1-7 (1992).
125.	2	F. Barany; Genetic disease detection and DNA amplification using cloned thermostable ligase; Proc. Natl. Acad. Sci.; 88:189-



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		PROPERTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
		APPLICANT TONG, ET AL.	
		FILING DATE AUGUST 24, 2001	GROUP 1636
		193 (1991).	
126.	Sc	Letsinger, et al.; Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture; Proc. Natl. Acad. Sci.; 86:6553-6556 (1989).	
127.	Sc	Lemaitre, et al.; Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site; Proc. Natl. Acad. Sci.; 84:648-652 (1987).	
128.	Sc	Krol, et al.; Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences; Bio/Techniques; 6(10):958-976 (1988).	
129.	Sc	G. Zon; Oligonucleotide Analogues as Potential Chemotherapeutic Agents; Pharmaceutical Research; 5(9):539-549 (1988).	
130.	Sc	Gautier, et al.; α -DNA IV: α -anomeric and β -anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding; Nucleic Acids Research; 15(16):6625-6641 (1987).	
131.	Sc	Inoue, et al.; Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides; 15:6131-6148 (1987).	
132.	Sc	Inoue, et al.; Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H; FEBS Lett.; 215(2):327-330 (1987).	
133.	Sc	Hermansson, et al.; Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation; Proc. Natl. Acad. Sci.; 85:7748-7752 (1988).	
134.	Sc	Benoist, et al.; In vivo sequence requirements of the SV40 early promoter region; Nature; 290:304-310 (1981).	
135.	Sc	Yamamoto, et al.; Identification of a functional promoter in the long terminal repeat of rous sarcoma virus; Cell; 22:787-797 (1980).	
136.	Sc	Wagner, et al.; Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1; Proc. Natl. Acad. Sci.; 78(3):1441-1445 (1981).	
137.	Sc	Brinster, et al.; Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs; Nature; 296:39-42 (1982).	
138.	Sc	Sarver, et al.; Ribozymes as potential anti-HIV-1 therapeutic agents; Science; 247:1222-1225 (1990).	
139.	Sc	J. J. Rossi; Making ribozymes work in cells; Current Biology; 4:469-471 (1994).	
140.	Sc	Haseloff, et al.; Simple RNA enzymes with new and highly specific endoribonuclease activities; Nature; 334:585-591 (1988).	
141.	Sc	Zaug, et al.; A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA; Science; 224:574-578 (1984).	
142.	Sc	Zaug, et al.; The intervening sequence RNA of tetrahymena is an enzyme; Science; 231:470-475 (1986).	
143.	Sc	Zaug, et al.; The tetrahymena ribozyme acts like an RNA restriction endonuclease; Nature; 324:429-433 (1986).	
144.	Sc	Been, et al.; One binding site determines sequence specificity of tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity; Cell; 47:207-216 (1986).	
145.	Sc	Smithies, et al.; Insertion of DNA sequences into the human chromosomal β -globin locus by homologous recombination; Nature; 317:230-234 (1985).	
146.	Sc	Thomas, et al.; Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells; Cell; 51:503-512 (1987).	
147.	Sc	Thompson, et al.; Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells; Cell; 56:313-321 (1989).	
148.	Sc	C. Helene; The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides; Anti-cancer drug design; 6:569-584 (1991).	



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10790A	SERIAL NO. 09/938,391
			APPLICANT TONG, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP 1636
149.	✓		Helene, et al.; Control of gene expression by triple helix-forming oligonucleotides; Ann. NY Acad. Sci.; 660:27-36 (1992).	
150.	✓		L. J. Maher, III; DNA triple-helix formation: An approach to artificial gene repressors?; Bioassays; 14(12):807-815 (1992).	
151.	✓		Linder, et al.; Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency; Clin. Chem. 43(2):254-266 (1997).	
152.	✓		Cruikshank, et al.; A lipidated anti-tat antibody enters living cells and blocks HIV-1 viral replication; J. Acquired Immune Deficiency Syndromes and Human Retrovirology; 14:193-203 (1997).	
153.	✓		O'Reilly, et al.; Endostatin: An endogenous inhibitor of angiogenesis and tumor growth; Cell; 88:277-285 (1997) XP000652213.	
154.	✓		Stein, et al.; Physicochemical Properties of Phosphorothioate Oligodeoxynucleotides; Nucleic Acids Research; 16:3209-3221 (1988).	
155.	✓		Griffin, et al.; The Humana Press Inc.; DNA Sequencing; 38:147-159 (1993).	
156.	✓		Ausubel F.M., et al.; Eds.; Current Protocols in Molecular Biology; Vol. 1, Green Publishing Associates Inc.	
157.	✓		Creighton; Proteins; Structures and Molecular Principles; W.H. Freeman and Company, NY, pp.34-49 (1983).	
158.	✓		Sheffield, et al.; Proc. Natl. Acad. Sci.; Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes; Vol. 86, pp. 232-236 (1989).	
159.	✓		Myers; Molecular Biology and Biotechnology: A comprehensive desk reference, VCH Publishers, New York; p. 833 (1995).	
160.	✓		Cohen, et al.; Adv. Chromatogr.; Emerging Technologies for Sequencing Antisense Oligonucleotides: Capillary Electrophoresis and Mass Spectrometry; 36:127-162 (1996).	
161.	✓		Maggio, E. (ed.); CC Press, Boca Ration FL; Enzyme-Immunoassay; (1980).	
EXAMINER			DATE CONSIDERED 9/15/03	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				